Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99.
ByAinvest
Thursday, Jul 31, 2025 10:38 am ET1min read
DXCM--
The analyst at Raymond James maintained the "Strong Buy" rating, indicating a high degree of confidence in DexCom's prospects. The raised price target of $102 represents a 2.02% increase over the previous target of $99, suggesting a bullish view on the stock's potential appreciation.
According to the latest financial report, DexCom delivered a solid second-quarter 2025 update, with adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus Estimate of 45 cents by 6.7%. Total revenues grew by 15.2% year over year, driven by strong category demand and a growing contribution from recent access wins, particularly for type 2 diabetes. Despite these positive results, shares of DXCM declined almost 5.5% during after-hours trading on July 30, 2025 [2].
The company also raised its outlook for 2025 revenues, expecting revenues to be in the range of $4.6-$4.625 billion, implying 14-15% year-over-year growth. This guidance was higher than the Zacks Consensus Estimate of $4.61 billion. DexCom expects adjusted gross margin to be approximately 62% and adjusted operating margin to be approximately 21% for the year [2].
Raymond James' latest update comes amid a broader positive sentiment from Wall Street analysts. Oppenheimer has also maintained its "Outperform" rating for DXCM and raised its price target to $102 from $95. The average target price for DXCM based on 26 analysts is $100.93, with a high estimate of $115.00 and a low estimate of $85.00 [1]. Additionally, the consensus recommendation from 28 brokerage firms is currently 1.7, indicating "Outperform" status [1].
The estimated GF Value for DXCM in one year is $169.00, suggesting an upside of 89.76% from the current price of $89.06 [1]. This estimate is based on the historical multiples the stock has traded at previously, as well as past business growth and future estimates of the business' performance.
In conclusion, DexCom Inc. continues to receive strong support from analysts, with Raymond James raising its price target and maintaining a "Strong Buy" rating. The company's solid second-quarter results and positive outlook for the year have contributed to the bullish sentiment among investors.
References:
[1] https://www.gurufocus.com/news/3022351/dexcom-dxcm-price-target-raised-by-oppenheimer-to-102-dxcm-stock-news
[2] https://www.nasdaq.com/articles/dexcom-stock-falls-despite-q2-earnings-beat-2025-sales-view-raise
OPY--
Dexcom: Raymond James Keeps Strong Buy, PT Raised to $102 from $99.
DexCom Inc. (DXCM) continues to receive a strong buy rating from Raymond James, with the firm raising its price target to $102 from $99. This upward revision reflects a positive outlook on the company's future performance and market position.The analyst at Raymond James maintained the "Strong Buy" rating, indicating a high degree of confidence in DexCom's prospects. The raised price target of $102 represents a 2.02% increase over the previous target of $99, suggesting a bullish view on the stock's potential appreciation.
According to the latest financial report, DexCom delivered a solid second-quarter 2025 update, with adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus Estimate of 45 cents by 6.7%. Total revenues grew by 15.2% year over year, driven by strong category demand and a growing contribution from recent access wins, particularly for type 2 diabetes. Despite these positive results, shares of DXCM declined almost 5.5% during after-hours trading on July 30, 2025 [2].
The company also raised its outlook for 2025 revenues, expecting revenues to be in the range of $4.6-$4.625 billion, implying 14-15% year-over-year growth. This guidance was higher than the Zacks Consensus Estimate of $4.61 billion. DexCom expects adjusted gross margin to be approximately 62% and adjusted operating margin to be approximately 21% for the year [2].
Raymond James' latest update comes amid a broader positive sentiment from Wall Street analysts. Oppenheimer has also maintained its "Outperform" rating for DXCM and raised its price target to $102 from $95. The average target price for DXCM based on 26 analysts is $100.93, with a high estimate of $115.00 and a low estimate of $85.00 [1]. Additionally, the consensus recommendation from 28 brokerage firms is currently 1.7, indicating "Outperform" status [1].
The estimated GF Value for DXCM in one year is $169.00, suggesting an upside of 89.76% from the current price of $89.06 [1]. This estimate is based on the historical multiples the stock has traded at previously, as well as past business growth and future estimates of the business' performance.
In conclusion, DexCom Inc. continues to receive strong support from analysts, with Raymond James raising its price target and maintaining a "Strong Buy" rating. The company's solid second-quarter results and positive outlook for the year have contributed to the bullish sentiment among investors.
References:
[1] https://www.gurufocus.com/news/3022351/dexcom-dxcm-price-target-raised-by-oppenheimer-to-102-dxcm-stock-news
[2] https://www.nasdaq.com/articles/dexcom-stock-falls-despite-q2-earnings-beat-2025-sales-view-raise
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet